Obesity Linked to Poor Outcome After Prostate Cancer
Biochemical and clinical failure rates increase with body mass index
MONDAY, June 26 (HealthDay News) -- Obese prostate cancer patients are more likely than non-obese patients to have biochemical failure or clinical recurrence of their disease after radiotherapy, according to a report published online June 26 in Cancer.
Sara S. Strom, Ph.D., from the University of Texas M.D. Anderson Cancer Center in Houston, and colleagues conducted a retrospective analysis of 873 patients receiving external-beam radiotherapy for localized prostate cancer to determine if obesity influences treatment outcome.
The researchers found a statistically significant association between body mass index and both biochemical and clinical failure with a hazard ratio of 1.04 and 1.05, respectively. Outcomes tended to be worse with increasing body mass index.
"The current findings validate the important role of obesity, not only on biochemical failure but also on clinical recurrence, and suggest a link to the biologic basis of tumor progression that can be therapeutically exploited," the authors conclude.